Jérémie Guedj

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Daouda Sissoko, Cédric Laouenan, Elin Folkesson et al. · PLoS Medicine · 2016 · 477 citations · Full text

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras et al. · Nature · 2020 · 354 citations · Full text

Antiviral Drug Development, Antiviral Therapy, Hydroxychloroquine Use +4

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Jérémie Guedj, Harel Dahari, Libin Rong et al. · Proceedings of the National Academy of Sciences · 2013 · 335 citations · Full text

Shorter Estimate, Viral Persistence, Hepatitis C +14

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

Nadège Néant, Guillaume Lingas, Quentin Le Hingrat et al. · Proceedings of the National Academy of Sciences · 2021 · 248 citations · Full text